Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 8, Issue 1 (2019)

A comparative study of Ondansetron and Palonosetron in the control of cisplatin induced emesis

Author(s):
Dr. S Anusha and Dr. P Saravanan
Abstract:
Chemotherapy induced nausea and vomiting (CINV) is one of the most undesirable treatment-related side effects among cancer patients. The antiemetic class of drugs which are very effective for the prevention and treatment of CINV is Selective 5-hydroxytryptamine (5-HT3) receptor antagonists. This randomized study compared the efficacy and safety of a single, intravenous dose of Palonosetron with daily intravenous doses of Ondansetron in the prevention of acute and delayed CINV in patients receiving highly emetogenic multiple-day cisplatin therapy in the Department of Oncology and Obstetrics and Gynaecology, Tertiary care hospital, Coimbatore, Tamilnadu. Patients treated with Palonosetron exhibited higher complete response rates, better control and prolonged protection of nausea and emetic episodes, less use of rescue medications and less impact on patients’ quality of life. Thus, Single fixed dose of Palonosetron is more effective than multiple doses of Ondansetron.
Pages: 300-305  |  179 Views  4 Downloads
How to cite this article:
Dr. S Anusha, Dr. P Saravanan. A comparative study of Ondansetron and Palonosetron in the control of cisplatin induced emesis. Pharma Innovation 2019;8(1):300-305.
The Pharma Innovation Journal